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6onducting clinical trials in trauma care is challenging. As new treatments become available, we are faced with the dilemma of how to confirm
their effectiveness and strengthen the evidence base. Randomized controlled trials are the criterion standard, but target groups in trauma care are
often small and specialized, making the classic approach to trial design difficult. Bayesian designs represent an innovative means of increasing
trial efficiency and conducting trials with more realistic sample sizes. This article examines the design of such trials, using the UK-REBOATrial
as an example. (J Trauma Acute Care Surg. 2017;83: 736–741. Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on
behalf of the American Association for the Surgery of Trauma.)CHALLENGES FACED BY TRAUMA TRIALS
Randomized controlled trials are considered the criterion stan-
dard for proving the effectiveness of new treatments. However,
clinical trials in trauma care pose a number of challenges. One
of the most important is sample size. Clinical trials aim to com-
pare two or more groups of patients, which should be as similar
as possible, other than for the treatment under investigation.
Trauma patients, however, represent a heterogeneous popula-
tion. Patients with traumatic brain injuries differ from those
who suffer from exsanguinating hemorrhage, and even patients
with more closely related diagnoses—for example, those with
pelvic fractures—may have very different presentations, needs,
and outcomes. As a result, the number of patients with compara-
ble injuries, both in terms of anatomy and physiology, is often
small. This can be problematic, because to detect meaningful
clinical differences using classic (also known as “frequentist”)
statistical approaches to clinical trial design, power calculations
often require sample sizes that are not easily achievable given the
size of the eligible patient population. This applies particularly
when the treatment under investigation is complex, as is the case
with many medical device trials, when they are being introduced
to highly specific subgroups of patients.
Resuscitative endovascular balloon occlusion of the aorta
(REBOA) falls into this category. Resuscitative endovascular
balloon occlusion of the aorta is a promising and conceptually
attractive new intervention, designed to reduce further blood loss
and improvemyocardial and cerebral perfusion, albeit at the cost of
an ischemic debt. However, to date, the effectiveness of REBOA10, 2017, Revised: June 1, 2017, Accepted: June 16, 2017
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-has only been evaluated using case series and nonrandomized
comparisons.1–5 Importantly, one large study, from Japan, has shown
that the technique may in fact be harmful,6 although the application
of REBOA in the Japanese setting may differ from how it is used in
Europe and North America.
Given this uncertainty, a randomized controlled trial
would be helpful as any potential confounding variables should
be equalized. We have recently designed such a trial, to evaluate
the effectiveness, and cost-effectiveness, of REBOA. Given the
very specific pool of patients for whom REBOAwould be con-
sidered appropriate, it became clear that the numbers required
for a traditional, frequentist trial design would not be feasible.
This prompted us to explore other randomized trial design op-
tions, and we eventually adopted a Bayesian group-sequential
design. The aim of this special commentary is to describe the de-
liberations that took place and the design eventually chosen, in
order to illustrate how such methods may be used to overcome
the problems posed by small populations such as those seen in
trauma care.
THE UK-REBOA TRIAL
The UK-REBOATrialwill compare standard major trauma
center treatment plus REBOAwith standard major trauma center
treatment alone, for trauma patients with confirmed or suspected
life-threatening torso hemorrhage. Patient recruitment is expected
to commence in October 2017. The total duration of the study
will be 4 years, including an initial 9-month feasibility assess-
ment phase (Fig. 1). The trial’s entry criteria include adult
trauma patients with confirmed or suspected life-threatening torso
hemorrhage, which is thought to be amenable to adjunctive
treatment with REBOA (zone I or III), presenting at major
trauma centers. The primary outcome is 90-day mortality, defined
as death within 90 days of injury, before or after discharge from
hospital. This outcome is intended to capture any late harmful
effects. Cost-effectiveness is also being addressed.
An analysis of national trauma registry data revealed that,
per year, an estimated 200 trauma patients in England might
benefit from the use of REBOA. Approximately 125 of these
present to major trauma centers.7 Ninety-day mortality was
33.5%. A standard sample size calculation for comparing twoJ Trauma Acute Care Surg
Volume 83, Number 4
Figure 1. Summary of UK-REBOA Trial design.
J Trauma Acute Care Surg
Volume 83, Number 4 Jansen et al.proportions showed that in order to demonstrate a 5% reduction
in mortality (from 33.5% to 28.5%), based on a two-sided α of
5% and 80% power, a total of 2,764 patients would be required
(1,382 in each arm). This equates to more than 20 years’ recruit-
ment of all available patients presenting to major trauma centers
in England. Given the number of patients who could, even in
theory, be recruited, it was clear that a traditional, frequentist de-
sign was simply not feasible.
TRADITIONAL APPROACHES TO REDUCING
SAMPLE SIZE
We therefore considered means of reducing the sample
size to a more realistic level, while ensuring the scientific integ-
rity of the trial. Parmar et al.8 have recently described a useful
framework for a systematic and constructive examination of
the options. Step 1, which is largely intuitive, considers “increas-
ing what is feasible,” including lengthening the accrual time,
broadening the eligibility criteria, and extending the collabora-
tion nationally and internationally. Step 2 considers common ap-
proaches to reducing sample size, such as using a primary
outcome, which is more “information heavy” (usually a contin-
uous outcome), defining a realistic and worthwhile (but larger)
target difference, and reducing power by small amounts. Step
3 explores less common approaches to reducing sample size,
such as relaxing α, moving to one-sided significance tests, and
including covariates in the design. Although this article provides
a very useful framework, and one that we would recommend is
reviewed, when applied to REBOA none of these approaches re-
sulted in a feasible trial design. Instead we decided to use a com-
bination of two other strategies that have occasionally been
suggested, but rarely implemented in trauma trials: adaptive
(and specifically group-sequential) methods9,10 and a shift to
the Bayesian paradigm. We discuss both of these in the follow-
ing sections.
GROUP-SEQUENTIAL DESIGNS
A group-sequential clinical trial design is a type of adap-
tive design that allows for one or several interim analyses of
the accruing data while recruitment is still ongoing, with the op-
tion to terminate the trial early if the intervention under study is© 2017 Wolters Kluwer Health, Inc. All rights reserved.found to be ineffective (“stopping for futility”) or even un-
safe.11,12 Some group-sequential designs also permit early stop-
ping for benefit when a clear and convincing treatment effect
manifests early on. These methods have the potential to speed
up trials and increase the efficiency of clinical research. When
using classic (frequentist) statistics, however, repeated interim
analyses of accruing data pose a multiplicity problem: the trial’s
overall Type I error rate α is inflated, unless statistical adjustments
are made, but these again reduce the efficiency of the design.
Bayesian statistics, in contrast, provide a very natural
framework for repeated data analyses, without the need for any
separate adjustments. Bayesian designs are thus particularly at-
tractive when there are safety concerns, which demand regular
analysis of the data. If an intervention is indeed harmful, then
the study should be stopped as soon as possible, to minimize
the number of patients exposed. Given the findings of the Japanese
study, this was an area of particular concern.
BAYESIAN CLINICAL TRIAL DESIGNS
The Bayesian approach to trial design is fundamentally
different.13When a clinical trial is being planned, there is usually
some existing prior knowledge regarding the effect of the inter-
vention under investigation, for example, from a pilot study or
case series. In a Bayesian trial, this existing prior knowledge
can be utilized and is represented by the prior probability distri-
bution (or, for short, the prior). New data are then gathered from
the trial itself (and also summarized in the form of a probability
distribution, often referred to as likelihood), and combined with
the prior, using Bayes’ theorem, yielding the posterior probabil-
ity distribution (or posterior for short), which represents the up-
dated knowledge after seeing the trial data. The definitions of
these terms are summarized in Table 1, and the combining of
probability distributions is shown in Figure 2. In effect, the prior
information and the trial results, as they emerge, are viewed as
a continuous stream of information, in which inferences can
be updated as new data become available. This concept is shown
in Figure 3.
Although widely used in other fields, the uptake of
Bayesian statistics by the medical sciences, and particularly
in clinical trial design, has been slow. This may be related to
the mathematical complexity of some Bayesian techniques,737
TABLE 1. Definitions
Term Definition
Prior (probability distribution) P(H) Probability that hypothesis H is true before observing data D
Posterior (probability distribution) P(H|D) Probability that hypothesis H is true given the observed data D
Likelihood P(D|H) Probability of observing this data D when hypothesis H is true
Marginal P(D) Probability of observing this data D under all possible hypotheses
Bayes’ theorem
P HjDð Þ ¼ PðHÞ*PðDjHÞP Dð Þ Posterior ¼ Prior*LikelihoodMarginal
Jansen et al.
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of a prior. The prior distribution plays a key role in Bayesian
analysis, but is often misunderstood. Conceptually, it is easy
to comprehend how previous knowledge, when combined
into what are known as strongly informative priors, could be
used to contextualize new data. When good prior information
exists, the Bayesian approach allows for such information to
be incorporated into the design and analysis of a trial, justify-
ing a smaller or shorter-duration trial, and thus increasing trial
efficiency. The major issues lie in how to decide what “good”
prior information is, how to determine an informative prior
that is acceptable for trialists and stakeholders, and how to
“weight” the prior knowledge in comparison to the new trial
data. All this is far from straightforward in practice, and even
more so when the information available is contradictory, and
comes from heterogeneous patient populations. Informative
priors, although conceptually attractive, are therefore some-
times regarded as inherently subjective and viewed with a de-
gree of suspicion. Given the conflicting prior evidence relating
to REBOA, and the confirmatory nature of the intended trial, we
therefore chose to use noninformative priors.
Noninformative priors (which are also known as flat or
weak priors, on account of the shape of their probability distri-
butions) avoid these issues, but cannot make use of existing
knowledge. Some regard the term “noninformative” as an un-
helpful misnomer (because a completely flat prior suggests thatFigure 2. Bayesian data analysis in action: the posterior is obtained b
prior, likelihood, and posterior are normal distributions. The influence
hence, the likelihood and posterior are very similar, whereas the stron
on the posterior. In both cases, the likelihood is based on a sample o
means are 0 in both cases, and the posterior means are 0.476 and 0.
738all values of the effect of the intervention are considered equally
likely, which is also information) and refer to these priors as “ref-
erence” priors instead. They are primarily used when there is no
prior information available, when the evidence is conflicting, or
for confirmatory trials, where the aim is to “let the data speak for
themselves.”
These priors carry very little information and thus have
only minimal influence on the posterior (Fig. 2A). Despite not
incorporating (much) prior knowledge, these types of trials are
often more efficient and appealing than frequentist designs.
The reason is that the Bayesian concept can be used for
iterative updating of the state of knowledge: starting with a
completely flat prior and adding data from the first patient (or
cohort of patients), the posterior is the same as the likelihood.
This posterior—which is now “informative”—then becomes
the prior for the next updating step when data from the next
patient (or cohort of patients) are added, and so on (Fig. 3).
Another major advantage of Bayesian methods is that they
provide intuitively comprehensible answers. One of the problems
with frequentist statistics is that p values and confidence intervals
are easy to misinterpret14–16 and when correctly interpreted often
do not give a useful answer to the question asked: a Bayesian
analysis yields the probability of a specific treatment effect given
the data, whereas a frequentist p value is the probability of a spe-
cific or more extreme treatment effect given the assumption of a
null hypothesis of no effect being true, which is convoluted andy combining the prior with the likelihood. In this example, all
of the weak prior (left hand panel) with Variance 2 is minimal;
g prior (right-hand panel) with Variance 0.1 has notable influence
f data with n = 10, mean 0.5, and (known) Variance 1. The prior
25, respectively.
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
Figure 3. Illustrative example of the iterative nature of a Bayesian sequential trial, with updating after every single patient. All prior,
likelihood, and posterior are normal distributions. After each patient, the prior and the data are combined, yielding the posterior, which
then becomes the prior for the next iteration. The initial prior is weak with variance σ2 = 2. The patient data were randomly
drawn from a normal distribution with mean 0.5 and (known) Variance 1.
J Trauma Acute Care Surg
Volume 83, Number 4 Jansen et al.hard to appreciate. And unlike frequentist confidence intervals,
Bayesian credible intervals are also straightforward to under-
stand: there is a 95% probability that the true value of the treat-
ment effect falls within the 95% credible interval, given the
observed data. Moreover, Bayesian designs can offer great flex-
ibility when it comes to formulating meaningful decision
criteria, for example, for declaring the success of a trial or for
stopping a sequential trial early.
SPECIFIC CONSIDERATIONS
In a Bayesian trial, we often present how a Bayesian anal-
ysis will perform given a set sample size. We therefore estimated
the number of patients whom we felt we would be able to recruit© 2017 Wolters Kluwer Health, Inc. All rights reserved.for the UK-REBOATrial, in a reasonable number of centers, in a
reasonable time. We calculated this number as 120, based on a
pilot phase comprising five major trauma centers, recruiting
over a period of 9 months, and a full trial phase comprising 10
major trauma centers, recruiting for 24 months (Fig. 1), based
on our registry analysis. One hundred twenty, therefore, became
our set sample size on which the expected performance of the
Bayesian design was assessed.
We adopted a group-sequential Bayesian design17 with
three stages, of 40 patients each, and two interim analyses after
40 and 80 randomized participants, and a final analysis after a
maximum of 120 randomized participants. We decided that the
trial should be stopped early if there is a high (posterior) probabil-
ity (90% or greater) that the 90-day survival odds ratio (OR) falls739
TABLE 2. Stopping and Success Probabilities and Expected Sample Sizes in UK-REBOA
OR Survival
Probability of Declaring
Expected Sample SizeFutility (1st) Futility (2nd) Futility (Final) Futility (Total) Success
0.70 58.2% 85.3% 13.0% 1.6% 99.8% 0% 46.6
0.75 59.8% 72.5% 20.6% 5.2% 98.3% 0% 53.8
0.80 61.4% 57.0% 24.7% 10.5% 92.2% 0% 64.5
0.85 62.8% 41.3% 23.0% 13.5% 77.8% 0% 77.8
0.90 64.1% 27.7% 17.1% 11.8% 56.5% 0.2% 91.0
0.95 65.3% 17.2% 10.4% 7.4% 35.0% 1.3% 102.1
1.00 66.5% 10.0% 5.3% 3.5% 18.7% 5.0% 109.9
1.05 67.6% 5.5% 2.3% 1.3% 9.0% 13.7% 114.7
1.10 68.6% 2.9% 0.9% 0.4% 4.1% 28.5% 117.4
1.15 69.5% 1.4% 0.3% 0.1% 1.8% 47.4% 118.8
1.20 70.4% 0.7% 0.1% 0% 0.8% 66.1% 119.4
1.25 71.3% 0.3% 0% 0% 0.3% 80.9% 119.7
1.30 72.1% 0.1% 0% 0% 0.1% 90.6% 119.9
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analysis. Resuscitative endovascular balloon occlusion of the aorta
will be declared “successful” if the probability that the 90-day sur-
vival OR exceeds 1 at the final analysis is 95% or greater.
We explored the trial’s operating characteristics based on
the data obtained from our registry analysis and assumed a con-
trol group (standard major trauma center treatment alone)
90-day survival rate of 66.5%.7 The design’s properties in terms
of the probabilities of stopping for futility, at each interim look,
and declaring success, for potential effect sizes from an OR of
0.7 (equating to a reduction in 90-day survival from 66.5% to
58.2%, i.e., REBOA causing harm) through to 1.3 (equating to
an increase in 90-day survival from 66.5% to 72.1%), and the
expected sample size (the number of patients expected to be ran-
domized under this scenario), are shown in Table 2. The proba-
bilities were computed using the R package gsbDesign.18
The probabilities of early stopping are high if REBOA re-
sults in markedly decreased 90-day survival, roughly 19% if
there is no difference to standard care (Table 2, highlighted in
blue) and less than 10% if REBOA is a success with OR 1.05
or greater (highlighted in yellow). The probability that success is
declared is less than 1.5% if REBOA is harmful with OR of 0.95
or less, exactly 5% if both treatments are equal (as specified in
our success criterion), greater than 60% if REBOA does well
(OR ≥1.2, highlighted in light green), and greater than 90% if it
does exceptionally well (OR ≥1.3, highlighted in dark green).
The expected sample size is directly related to the probability of
early stopping.
DISCUSSION
Conducting clinical trials in trauma care is challenging.
As new treatments become available, we are faced with the di-
lemma of how to confirm their effectiveness and strengthen
the evidence base. Target groups in trauma care are often small
and specialized, making the classic approach to trial design dif-
ficult. As a result, studies may not happen at all, often because of
infeasible sample sizes, or may be underpowered.
One possible solution is to combine the results of such
studies, if available, in meta-analyses. However, meta-analyses740have their own limitations—they require a sufficient number
of primary studies to be available, and heterogeneity may be
problematic. An alternative solution is a complete shift in statis-
tical paradigm, from traditional frequentist to Bayesian designs,
using innovative methods such as the Bayesian group-sequential
design that we implemented for UK-REBOA.
Conceptually, meta-analysis and Bayesian updating share
similarities: Both techniques combine information in order to
obtain the current best estimate about the treatment effect of in-
terest. Under a Bayesian framework, one could—at least in
theory—construct a prior that captures and represents all avail-
able information about the treatment effect (such as estimates
from previous trials) and update it with new trial data so that
the posterior would be broadly equivalent to an updated meta-
analysis, but of course it would pose challenges such as how to
weight the prior information in relation to the emerging trial
data. Bayesian updating does not make meta-analysis obsolete,
as the goal of the latter is not only to aggregate evidence and es-
timate a treatment effect but also to assess consistency or hetero-
geneity between single trials. Furthermore, meta-analysis can be
conducted with Bayesian methods as they are well suited to flex-
ibly modeling complex hierarchical relationships.19
When considering the design of primary research, Bayesian
clinical trial designs represent an innovative means of increasing
trial efficiency and conducting trials with more realistic sample
sizes, especially when the conduct of a trial would otherwise be
infeasible, along with other benefit such as straightforward inter-
pretability. The use of these designs is increasing, and both the
Food and Drug Administration and the European Medicines
Agency have released guidance relating to the use of Bayesian
clinical trials,20,21 but despite such endorsements, Bayesian de-
signs are often still viewed as too unconventional or difficult.
Medical devices are unusual in that regulatory approval does
not require proof of effectiveness, resulting in their rapid prolifer-
ation. Buxton’s law of the evaluation of new technologies and
devices—which states that “it is always too early [for rigorous
evaluation] until, unfortunately, it’s suddenly too late”22—
unfortunately often applies in trauma care. Bayesian clinical trial
designs are an attractive alternative to case series and poorly
controlled retrospective comparisons.© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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